1. What Is the IL-17 Inhibitors Market?
The IL-17 Inhibitors Market covers biologic therapies targeting the interleukin-17 pathway including IL-17A inhibitors, IL-17 receptor inhibitors, and dual IL-17A/F inhibitors used across psoriasis, psoriatic arthritis, ankylosing spondylitis, and nr-axial spondyloarthritis. Dermatologists, rheumatologists, and immunology specialists deploy IL-17 inhibitors as established second-line therapy following TNF inhibitor inadequate response and increasingly as first-line biologic options. The market includes secukinumab, ixekizumab, bimekizumab, and emerging pipeline agents.
2. IL-17 Inhibitors Market Size & Forecast
3. Emerging Technologies
- Subcutaneous autoinjector formulations enabling patient self-administration with extended maintenance dosing intervals improving patient adherence.
- Biosimilar secukinumab development entering the pipeline as Cosentyx approaches patent expiration in major markets.
- Combination IL-17 inhibitor plus IL-23 inhibitor regimens in severe refractory psoriasis and psoriatic arthritis being evaluated in clinical trials.
- IL-17 pathway biomarkers identifying patient populations most likely to achieve complete skin clearance with IL-17 inhibitor therapy.
Similar technologies are also transforming adjacent markets. Learn more in our Rheumatoid ARthritis Drugs Market.
4. Key Market Opportunity
Bimekizumab commercial expansion in psoriasis and psoriatic arthritis represents the most differentiated growth opportunity based on superior clearance data. Spondyloarthropathy indication expansion in rheumatology represents the largest new prescriber population growth opportunity. First-line biologic positioning across psoriasis and psoriatic arthritis is the largest patient volume expansion driver.
5. Top Companies in the IL-17 Inhibitors Market
The following organisations hold leading positions in the IL-17 Inhibitors Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- Novartis
- Eli Lilly
- UCB
- AbbVie
- Johnson and Johnson
- AstraZeneca
- Sandoz
- Amgen
- LEO Pharma
- Boehringer Ingelheim
6. Market Segmentation
The IL-17 Inhibitors Market is analysed across 5 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Mechanism Subtype | IL-17A Selective Inhibitors IL-17A and IL-17F Dual Inhibitors IL-17 Receptor Inhibitors Next-Generation Pipeline Agents |
| By Indication | Plaque Psoriasis Psoriatic Arthritis Ankylosing Spondylitis Non-Radiographic Axial SpA Hidradenitis Suppurativa |
| By Treatment Line | First-Line Biologic Second-Line After TNF Failure Third-Line Therapy |
| By End-User | Dermatology Clinics Rheumatology Practices Specialty Pharmacies |
| By Geography | North America The U.S. Canada Europe The UK Germany France Italy Spain Denmark Netherlands Finland Sweden Norway Russia Austria Poland Rest of Europe Asia Pacific China Japan India South Korea Australia Indonesia Vietnam Philippines Singapore Taiwan Thailand Rest of Asia Pacific Latin America Brazil Mexico Argentina Rest of South America Middle East and Africa GCC Countries Israel South Africa Rest of Middle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the IL-17 Inhibitors Market trajectory over the forecast period:
Indication expansion across spondyloarthropathy spectrum is driving IL-17 inhibitor market growth beyond established psoriasis applications.Ankylosing spondylitis and non-radiographic axial spondyloarthritis approvals for secukinumab and ixekizumab are expanding the prescribing rheumatology patient population substantially. The spondyloarthropathy expansion is creating substantial new rheumatology IL-17 inhibitor prescribing beyond dermatology-driven psoriasis applications.
Bimekizumab dual IL-17A/F inhibition is achieving superior psoriasis clearance rates versus established IL-17A-only inhibitors.UCB bimekizumab demonstrating higher PASI 100 rates than secukinumab and ixekizumab is gaining prescribing share in biologic-experienced psoriasis patients. The superior clearance differentiation is creating competitive pressure on established IL-17A inhibitors while expanding the overall IL-17 inhibitor category.
First-line biologic positioning is advancing for IL-17 inhibitors as dermatologists and rheumatologists increasingly select IL-17 inhibitors as initial biologic therapy based on superior skin and joint clearance data versus TNF inhibitors.The first-line positioning shift expands the addressable patient population beyond traditional TNF-failure patient populations driving sustained market growth across the IL-17 inhibitor category.
For related market intelligence, see the Psoriasis Biologics Market.
8. Segmental Analysis
By agent, the secukinumab segment dominated the IL-17 Inhibitors Market in 2025, as Novartis Cosentyx represents the first-approved and most broadly adopted IL-17A inhibitor with the largest patient volume across psoriasis, psoriatic arthritis, and spondyloarthropathy indications globally.
By indication, the ankylosing spondylitis segment is projected to register the highest growth rate through 2034, as spondyloarthropathy indication expansion combined with first-line biologic positioning in rheumatology is driving the fastest-growing IL-17 inhibitor prescribing growth outside established psoriasis applications.
9. Regional Analysis
Regional demand patterns across the IL-17 Inhibitors Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America dominated the IL-17 Inhibitors Market in 2025, accounting for around 45 percent of global revenue. The United States dermatology and rheumatology prescribing infrastructure drives substantial IL-17 inhibitor utilization. Novartis Cosentyx, Eli Lilly Taltz, and UCB Bimzelx generate substantial U.S. commercial revenue. Moreover, U.S. specialty pharmacy infrastructure supports efficient IL-17 inhibitor distribution across dermatology and rheumatology treatment settings.
Highest CAGR Region
Europe is projected to register the highest CAGR in the IL-17 Inhibitors Market through 2034. European rheumatology and dermatology prescribing infrastructure combined with broad biologic reimbursement policies drives systematic IL-17 inhibitor adoption. UCB Bimzelx European approval is driving competitive market dynamics. Moreover, European spondyloarthropathy treatment guideline adoption of IL-17 inhibitors is expanding the rheumatology prescriber base significantly.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology Adoption Trends and Innovation Tracking
- • Custom Company Profiling and Benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country-Level Opportunity Mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The IL-17 Inhibitors Market was valued at USD 12.47 Bn in 2025 and is projected to reach USD 32.96 Bn by 2034, growing at a CAGR of 11.4% over the 2026–2034 forecast period.
The IL-17 Inhibitors Market is projected to grow at a CAGR of 11.4% from 2026 to 2034.
North America dominated the IL-17 Inhibitors Market in 2025, accounting for around 45 percent of global revenue.
The leading companies in the IL-17 Inhibitors Market include Novartis, Eli Lilly, UCB, AbbVie, Johnson and Johnson, AstraZeneca, Sandoz, Amgen, LEO Pharma, Boehringer Ingelheim.
Indication expansion across spondyloarthropathy spectrum is driving il-17 inhibitor market growth beyond established psoriasis applications.
By agent, the secukinumab segment dominated the IL-17 Inhibitors Market in 2025, as Novartis Cosentyx represents the first-approved and most broadly adopted IL-17A inhibitor with the largest patient volume across psoriasis, psoriatic arthritis, and spondyloarthropathy indications globally.
How to Order
Choose Your Package
Condensed edition of this study for students, researchers and academic institutions.
- Condensed edition of the full study
- For students, researchers & academic institutions
- Valid student ID or institutional email required
- Educational, non-commercial use only
The competitive landscape, including key market participants, company size, market positioning, and comparative competitive standing.
- 15 in-depth company profiles
- Company overview
- Product and brand portfolio mapped per company
- Revenue for the last 3 FYs with key financial metrics
- Segmental revenue and regional revenue breakdown
- Market presence, key geographies & end-use industries
- Recent developments
- Key capabilities, differentiators & strategic positioning
- SWOT Analysis
- 15-company market share analysis
- 2025 market share by company
- Company revenue in USD
- Competitive quadrant positioning
- Product portfolio comparison
The complete forecast model, including every study table, is provided in clean, formula-ready Excel format across 4 segmentation axes. Select the geographic coverage required for your analysis.
- One country, broken out across 4 segmentation axes
- 2025 base year, 2026–2034 forecast, CAGR per line
- Excel workbook
- Region totals plus every country inside that region
- All axes, all years, CAGR per line
- Cross-country comparison sheet included
- Excel workbook
- Every forecast table in the study
- Global, regional and country views in one workbook
- Segment share and CAGR pivots included
- Excel workbook
The full syndicated study. Every chapter, every region, every country, plus the complete Excel model, methodology and appendix.
- Executive summary, market scope & segmental snapshot
- Market dynamics: drivers, restraints, opportunities, challenges
- Quantitative analysis across 4 segmentation axes
- Regional analysis
- Competitive landscape, market share & company revenue mapping
- Includes the full Global Excel Data Pack
- Complete research methodology, assumptions & appendix
TAM/SAM/SOM sizing, M&A target screening, patent & IP analysis, supply-chain resilience mapping, ESG roadmaps and other bespoke strategic work.
- TAM / SAM / SOM sizing
- M&A target screening
- Patent & IP analysis
- Supply-chain resilience mapping
- ESG roadmaps & other bespoke strategic work
Not sure which package fits? Tell us the decision you are making and an analyst will recommend the smallest package that answers it. Talk to an analyst.
Ordering Process
Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.